{"transactions":[{"id":726374,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:00:41.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001486373-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000148637326000005/primarydocument.xml","form_type":"4"}},{"id":1107913,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T20:25:41.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":4.79,"value":119750.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":4.79,"exercise_date":"2026-06-17","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-25-004893","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218025004893/primarydocument.xml","form_type":"4"}},{"id":1454545,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-15T20:11:44.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."}],"balance_after":65000,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-24-005718","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218024005718/primarydocument.xml","form_type":"4/A","original_submission_date":"2024-06-07"}},{"id":1467172,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-28T20:03:47.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":5.52,"value":88320.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":5.52,"exercise_date":"2025-06-26","expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-24-005358","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218024005358/primarydocument.xml","form_type":"4"}},{"id":1486695,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:21:50.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":54278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":54278,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":54278},"source":{"system":"sec-edgar","filing":"0001562180-24-004840","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218024004840/primarydocument.xml","form_type":"4"}},{"id":1809877,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:53.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":4.9984,"value":3413.9072,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":9.9216,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012136","document":"form4-08112023_040826.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000141588923012136/form4-08112023_040826.xml","form_type":"4"}},{"id":1809876,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:53.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":6.6439,"value":4537.7837,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":8.2761,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012136","document":"form4-08112023_040826.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000141588923012136/form4-08112023_040826.xml","form_type":"4"}},{"id":1846468,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T00:14:15.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":8.7,"exercise_date":"2024-06-21","expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-23-005479","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218023005479/primarydocument.xml","form_type":"4"}},{"id":1860442,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:33:24.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023."}],"balance_after":65000,"derivative":{"exercise_price":6.7,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-23-005027","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218023005027/primarydocument.xml","form_type":"4"}},{"id":1867177,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T22:01:14.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":12649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":12649,"derivative":{"exercise_price":30.92,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":12649},"source":{"system":"sec-edgar","filing":"0001714899-23-000093","document":"wk-form4_1686002460.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000093/wk-form4_1686002460.xml","form_type":"4"}},{"id":1867176,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T22:01:14.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 unvested RSUs."}],"balance_after":26564,"source":{"system":"sec-edgar","filing":"0001714899-23-000093","document":"wk-form4_1686002460.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000093/wk-form4_1686002460.xml","form_type":"4"}},{"id":1882571,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-22T20:20:12.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024"}],"balance_after":8888,"derivative":{"exercise_price":0.6366,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-23-008492","document":"form4-05222023_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000141588923008492/form4-05222023_040501.xml","form_type":"4"}},{"id":2224077,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-06-23T01:00:24.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":13.81,"exercise_date":"2023-06-21","expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-22-005318","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218022005318/primarydocument.xml","form_type":"4"}},{"id":2239037,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-08T22:35:11.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022."}],"balance_after":65000,"derivative":{"exercise_price":4.95,"expiration_date":"2032-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-22-004942","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218022004942/primarydocument.xml","form_type":"4"}},{"id":2242446,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-07T00:09:02.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17959,"derivative":{"exercise_price":24.27,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":17959},"source":{"system":"sec-edgar","filing":"0001714899-22-000095","document":"wf-form4_165456052861515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000095/wf-form4_165456052861515.xml","form_type":"4"}},{"id":2242445,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T00:09:02.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":5986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,035 shares received in prior distributions-in-kind made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":22348,"source":{"system":"sec-edgar","filing":"0001714899-22-000095","document":"wf-form4_165456052861515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000095/wf-form4_165456052861515.xml","form_type":"4"}},{"id":2253373,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T21:00:30.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023"}],"balance_after":8888,"derivative":{"exercise_price":0.7632,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-22-005826","document":"form4-05272022_050508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000141588922005826/form4-05272022_050508.xml","form_type":"4"}},{"id":2634029,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-14T20:52:56.000Z","date":"2021-07-13","kind":"grant","acquired":true,"shares":12530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors."}],"balance_after":12530,"derivative":{"exercise_price":9.4,"exercise_date":"2022-07-13","expiration_date":"2031-07-12","underlying":"Common Stock","underlying_shares":12530},"source":{"system":"sec-edgar","filing":"0001562180-21-004932","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218021004932/primarydocument.xml","form_type":"4"}},{"id":2653414,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T11:15:13.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":8888,"price":9.97,"value":88613.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022."}],"balance_after":8888,"derivative":{"exercise_price":9.97,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-21-003236","document":"form4-06282021_070600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000141588921003236/form4-06282021_070600.xml","form_type":"4"}},{"id":2681031,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-04T22:31:25.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":6222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":6222,"derivative":{"exercise_price":63.76,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":6222},"source":{"system":"sec-edgar","filing":"0001209191-21-038374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038374/doc4.xml","form_type":"4"}},{"id":2681030,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T22:31:25.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":5327,"source":{"system":"sec-edgar","filing":"0001209191-21-038374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038374/doc4.xml","form_type":"4"}},{"id":2683428,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-04T00:51:25.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":3253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3253},"source":{"system":"sec-edgar","filing":"0001209191-21-038035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038035/doc4.xml","form_type":"4"}},{"id":2683427,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T00:51:25.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":3253,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3253,"source":{"system":"sec-edgar","filing":"0001209191-21-038035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038035/doc4.xml","form_type":"4"}},{"id":2850053,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T23:58:25.000Z","date":"2021-02-03","kind":"grant","acquired":false,"shares":23591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in full on February 3, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."}],"balance_after":23591,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":23591},"source":{"system":"sec-edgar","filing":"0000899243-21-007191","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000089924321007191/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-05"}},{"id":2876613,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T22:16:53.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on February 3, 2022."}],"balance_after":14000,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-21-005072","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000089924321005072/doc4.xml","form_type":"4"}},{"id":3120563,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-05T21:58:49.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":3253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":3253,"derivative":{"underlying":"Common Stock","underlying_shares":3253},"source":{"system":"sec-edgar","filing":"0001209191-20-034764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120034764/doc4.xml","form_type":"4"}},{"id":3120562,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T21:58:49.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":15183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":15183,"derivative":{"exercise_price":28.82,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":15183},"source":{"system":"sec-edgar","filing":"0001209191-20-034764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120034764/doc4.xml","form_type":"4"}},{"id":3506465,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-31T22:28:57.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":27245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date."}],"balance_after":27245,"derivative":{"exercise_price":19.5,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":27245},"source":{"system":"sec-edgar","filing":"0001209191-19-033722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919119033722/doc4.xml","form_type":"4"}},{"id":3703994,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T21:02:08.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":7900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents non-qualified stock option to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy."}],"balance_after":7900,"derivative":{"exercise_price":18.24,"exercise_date":"2019-12-31","expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":7900},"source":{"system":"sec-edgar","filing":"0001562180-19-000190","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218019000190/primarydocument.xml","form_type":"4"}},{"id":3703993,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-04T21:02:08.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":2270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest as to 100% of the shares on December 31, 2019 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,270 restricted stock units."}],"balance_after":4540,"source":{"system":"sec-edgar","filing":"0001562180-19-000190","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000156218019000190/primarydocument.xml","form_type":"4"}},{"id":3848505,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-10T00:12:12.000Z","date":"2018-08-07","kind":"grant","acquired":true,"shares":7900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7900,"derivative":{"exercise_price":14.8,"exercise_date":"2018-12-31","expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":7900},"source":{"system":"sec-edgar","filing":"0001104659-18-051029","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000110465918051029/a4.xml","form_type":"4"}},{"id":3848504,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-10T00:12:12.000Z","date":"2018-08-07","kind":"grant","acquired":true,"shares":2270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest as to 100% of the shares on December 31, 2018. Each restricted stock unit represents the right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 2,270 restricted stock units."}],"balance_after":2270,"source":{"system":"sec-edgar","filing":"0001104659-18-051029","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000110465918051029/a4.xml","form_type":"4"}},{"id":3892696,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T22:27:52.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":27830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date."}],"balance_after":27830,"derivative":{"exercise_price":18.92,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":27830},"source":{"system":"sec-edgar","filing":"0001209191-18-038154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919118038154/doc4.xml","form_type":"4"}},{"id":4138047,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-12-08T22:54:38.000Z","date":"2017-12-07","kind":"grant","acquired":true,"shares":47165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":47165,"derivative":{"exercise_price":18,"expiration_date":"2027-12-06","underlying":"Common Stock","underlying_shares":47165},"source":{"system":"sec-edgar","filing":"0001209191-17-064804","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919117064804/doc4.xml","form_type":"4"}},{"id":4228543,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-21T20:17:20.000Z","date":"2017-08-17","kind":"other","acquired":true,"shares":1686,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 17, 2017, Flagship Ventures Fund IV, L.P. (\"Flagship IV\") and Flagship Ventures Fund IV-Rx, L.P. (\"Flagship IV-Rx\") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC (\"Flagship IV LLC\"), pro rata and without consideration, 1,361,400 shares and 340,349 shares, respectively, of the Issuer's common stock.  Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 57,022 shares and 11 shares it received from Flagship IV and Flagship IV-Rx, respectively.  Mr. Cole, a member of Flagship IV LLC, received 1,686 shares through such distribution."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 17, 2017, Flagship Ventures Fund IV, L.P. (\"Flagship IV\") and Flagship Ventures Fund IV-Rx, L.P. (\"Flagship IV-Rx\") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC (\"Flagship IV LLC\"), pro rata and without consideration, 1,361,400 shares and 340,349 shares, respectively, of the Issuer's common stock.  Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 57,022 shares and 11 shares it received from Flagship IV and Flagship IV-Rx, respectively.  Mr. Cole, a member of Flagship IV LLC, received 1,686 shares through such distribution."}],"balance_after":3171,"source":{"system":"sec-edgar","filing":"0001012975-17-000637","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000101297517000637/edgar.xml","form_type":"4"}},{"id":4277533,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35372,"kind":"person","name":"Cole Douglas G.","position":1,"cik":"0001486373","reported_name":"Cole Douglas G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-19T20:15:23.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018."}],"balance_after":11538,"derivative":{"exercise_price":15.63,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-17-009264","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486373/000117911017009264/edgar.xml","form_type":"4"}}]}